Aditxt, Inc. (ADTX) has issued an update.
Aditxt, Inc. has entered into an agreement to acquire all issued and outstanding shares of Appili Therapeutics, Inc. through its subsidiary Adivir, Inc. in a transaction featuring both cash and stock considerations. Appili shareholders are set to receive $0.0467 per share and a fractional common stock of Aditxt, totaling $5,668,222 and 332,876 shares, respectively. The transaction is structured as a statutory plan of arrangement and is contingent upon customary closing conditions, including Appili shareholder approval and a minimum of $20 million in financing by Aditxt. This strategic move is expected to create value for shareholders, with representations, warranties, and covenants typical for such deals, allowing for a smooth acquisition process barring any material adverse changes or legal impediments.
Learn more about ADTX stock on TipRanks’ Stock Analysis page.
